Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug wholesaling has no practical alternative, FTC says in wholesaler merger federal trial.

This article was originally published in The Tan Sheet

Executive Summary

DRUG WHOLESALING HAS NO PRACTICAL ALTERNATIVE, FTC argues, leaving pharmacies and hospitals with no choice but to accept higher post-merger prices. In opening arguments before a D.C. federal court June 9 seeking to halt the mergers of McKesson/AmeriSource and Cardinal Health/Bergen Brunswig, Federal Trade Commission Bureau of Competition Assistant Director Michael Antalics said independent retail pharmacies and hospitals warehouse less than 1% of their drugs. The fact some large drug chains self-warehouse is irrelevant, he maintained, since they only keep in stock the 2,000 SKUs with the highest turnover and rely on wholesalers for the remaining 18,000 SKUs.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel